BIONTECH CMO DR. TÜRECI: WE WILL PUBLISH MORE DATA ON PHASE III TRIAL IN A COUPLE OF DAYS
WE ARE DISTRIBUTING BY LORRY OR PLANE, IF DISRUPTED BY THE TRANSITION PERIOD ENDING WE'LL FIND ANOTHER ROUTE.
WE ARE ASSESSING IN A CLINICAL FASHION CERTAIN BIOMARKERS TO ASSESS PREVENTION FROM INFECTION, WE WILL BE ABLE TO DISCUSS RESULTS ON THIS IN 3-6 MONTHS
WE HAVE INCLUDED IN THE TRIAL PEOPLE PREVIOUSLY INFECTED WITH el bichito-19, WE DON'T SEE ANY DIFFERENCES IN THE SAFETY PROFILE COMPARED TO PEOPLE WHO HAVE NOT PREVIOUSLY BEEN INFECTED.
THE VACCINE WAS STUDIED IN PEOPLE WITH DIABETES, PAST CANCER, STABLE COMORBIDITIES.
Salu2